Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
22.8
Year-on-year increase in operating income (%)Wording
Conditional
How definitive the wording is.Contents of this document
Summary of Q&AFiscal year ending March 20268 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net SalesAmount not stated+7.7%
Operating profitAmount not stated+22.8%
Ordinary incomeAmount not stated
Net incomeAmount not stated
Full-year earnings forecast
Fiscal year ending March 2027
Net Sales
¥24,000 million
Operating profit
¥1,200 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Full-year plan achievedKey points of the Q&AKey questions raised by investors at the briefing and the company's answers
- Factors behind the increase in revenue and operating profit
- Factors behind the decline in ordinary profit and net income
- Order backlog and project inquiries
- Assumptions underlying the fiscal year ending March 2027 forecast
- Background to the establishment of キーウェアメディカル株式会社 and its outlook
- Dividend policy and shareholder returns
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Continued development demand from existing customers, development demand driven by digital transformation, the securing of large fixed-price projects, execution of orders received in the previous fiscal year, new orders, and improved development efficiencyNew initiatives
- キーウェアメディカル株式会社 established on 15 January 2026
- The medical solutions business was transferred to キーウェアメディカル株式会社 through an absorption-type company split effective 1 April 2026
- Investment to strengthen the human capital and information security frameworks
- Annual dividend for the fiscal year ending March 2027 is expected to increase to ¥40 per share
Medium-term management plan targets
Dividend payout ratio of at least 35%Orders received and order backlog
Order backlog as of 31 March 2026 declined from the end of the previous fiscal year (amount: Not disclosed)Annual Dividend
Fiscal year ending March 2026
Annual¥34 per share
Fiscal year ending March 2027
Annual¥40 per share
Interim¥20 per share
End of period¥20 per share
Payout ratio
Fiscal year ending March 202635.4 %
Fiscal year ending March 202741.3 %
| Item | Details |
|---|---|
| Document type | Summary of Q&A |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Net Sales | 非開示 (YoY +7.7%) |
| Operating profit | 非開示 (YoY +22.8%) |
| Ordinary income | 非開示 |
| Net income | 非開示 |
| Full-year earnings forecast | Fiscal year ending March 2027 Net Sales ¥24,000 million / Operating profit ¥1,200 million / Ordinary income Not disclosed / Net income Not disclosed |
| Self-assessment against the plan | Full-year plan achieved |
| Assumptions Underlying the Business Outlook | Continued development demand from existing customers, development demand driven by digital transformation, the securing of large fixed-price projects, execution of orders received in the previous fiscal year, new orders, and improved development efficiency |
| Medium-term management plan targets | Dividend payout ratio of at least 35% |
| Annual Dividend | Fiscal year ending March 2026 Annual ¥34 per share / Fiscal year ending March 2027 Annual ¥40 per share / Interim ¥20 per share / End of period ¥20 per share |
| Payout ratio | Fiscal year ending March 2026 35.4 % / Fiscal year ending March 2027 41.3 % |
| Orders received and order backlog | Order backlog as of 31 March 2026 declined from the end of the previous fiscal year (amount: Not disclosed) |
| Key points of the Q&A | Factors behind the increase in revenue and operating profit, Factors behind the decline in ordinary profit and net income, Order backlog and project inquiries, Assumptions underlying the fiscal year ending March 2027 forecast, Background to the establishment of キーウェアメディカル株式会社 and its outlook, Dividend policy and shareholder returns |
| New initiatives | キーウェアメディカル株式会社 established on 15 January 2026, The medical solutions business was transferred to キーウェアメディカル株式会社 through an absorption-type company split effective 1 April 2026, Investment to strengthen the human capital and information security frameworks, Annual dividend for the fiscal year ending March 2027 is expected to increase to ¥40 per share |
Items this document does not state (16)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterProgress against full-year forecastSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookFinancial targetsAcquisition of treasury sharesCapital expendituresMarket Size / Share
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue benefited from orders from existing customers, transportation and healthcare projects, public-sector and IoT projects, large SI projects, and projects for the retail and wholesale sectors. Operating profit benefited not only from revenue growth but also from higher order unit prices, improved development productivity, and stronger project management. The decline in ordinary profit was attributed mainly to the absence of equity-method investment income, while the decline in net income was primarily due to the reversal of the gain on the sale of shares in affiliates recorded in the previous fiscal year.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.